Skip to main content

Table 1 Currently available anti-VEGF therapies

From: Pipeline therapies for neovascular age related macular degeneration

Generic Brand name, manufacturer Target/mechanism
Pegaptanib sodium Macugen; Bausch and Lomb, Rochester, New York 165 isoform of VEGF-A
Bevacizumab Avastin; Genentech, San Francisco, California All isoforms of VEGF-A
Ranibizumab Lucentis; Genentech, South San Francisco, California All isoforms of VEGF-A
Aflibercept Eylea; Regeneron, Tarrytown, New York VEGF-A and B, placental growth factor (PGF)
Brolucizumab Beovu; Novartis, Logo, Basel VEGF-A